11671_2017_2346_MOESM3_ESM.tif (1.34 MB)
Additional file 3: Figure S2. of Improved Antitumor Efficacy and Pharmacokinetics of Bufalin via PEGylated Liposomes
figure
posted on 2017-11-09, 05:00 authored by Jiani Yuan, Xuanxuan Zhou, Wei Cao, Linlin Bi, Yifang Zhang, Qian Yang, Siwang WangCharacteristic chromatogram of bufalin in plasma. (a) Blank plasma. (b) Blank plasma spiked with bufalin. (c) Blank plasma spiked with bufalin and resibufogenin (as internal standard). (d) Plasma samples spiked with resibufogenin 30Â min after intravenous administration of bufalin entity. (e) Plasma samples spiked with resibufogenin 30Â min after intravenous administration of bufalin-loaded liposomes. (f) Plasma samples spiked with resibufogenin 30Â min after intravenous administration of bufalin-loaded PEGylated liposomes. (1) Bufalin; (2) Resibufogenin. (TIFF 1372 kb)